Hope and Challenges: Immunotherapy in <i>EGFR</i>-Mutant NSCLC Patients
EGFR tyrosine kinase inhibitors (TKIs) are the preferred initial treatment for non-small cell lung cancer (NSCLC) patients harboring sensitive <i>EGFR</i> mutations. Sadly, remission is transient, and no approved effective treatment options are available for EGFR-TKI-advanced <i>EG...
Main Author: | Dan Yan |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-10-01
|
Series: | Biomedicines |
Subjects: | |
Online Access: | https://www.mdpi.com/2227-9059/11/11/2916 |
Similar Items
-
Immunotherapy strategies for EGFR-mutated advanced NSCLC after EGFR tyrosine-kinase inhibitors failure
by: Xingyuan Li, et al.
Published: (2023-10-01) -
Efficacy and safety of immunotherapy in EGFR-mutant advanced non-small cell lung cancer: A retrospective study
by: Tingting Tu, et al.
Published: (2023-08-01) -
The Presence of Concomitant Mutations Affects the Activity of EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) Patients
by: Anna Maria Rachiglio, et al.
Published: (2019-03-01) -
Advances in the Treatment of EGFR Exon 20ins Mutant NSCLC
by: Meiyi XU, et al.
Published: (2023-02-01) -
Intrinsic Resistance to EGFR-Tyrosine Kinase Inhibitors in <i>EGFR</i>-Mutant Non-Small Cell Lung Cancer: Differences and Similarities with Acquired Resistance
by: Eric Santoni-Rugiu, et al.
Published: (2019-07-01)